Article: ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available.

- Provides Rapid Control of Agitation -

PRINCETON, N.J., and TOKYO, Dec. 12 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of ABILIFY(R) (aripiprazole) Injection, an injectable form of ABILIFY, for intramuscular use. ABILIFY Injection provides rapid control of agitation in adults with schizophrenia or bipolar mania at primary endpoint (2 hours). The U.S. Food and Drug Administration (FDA) approved ABILIFY Injection on September 20, 2006.

The urgent nature of acute agitation requires immediate assessment and intervention. ABILIFY Injection provides healthcare professionals with the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!